Abstract Library

#4459 Sequential alkylating therapy and pembrolizumab induce near-complete response in high tumour mutational burden pancreatic neuroendocrine tumour: A case report

Introduction: Traditional treatment for neuroendocrine tumours (NETs), including surgery, somatostatin therapy, and targeted therapy, often fails in advanced disease. Alkylating therapy can increase tumour mutational burden (TMB), and the recent KEYNOTE-158 study approved pembrolizumab for advanced solid tumours with a high TMB.

Conference:

Presenting Author:

Authors: Paranjpe I, Hornbacker K, Vadde S, Fisher G, Shaheen S,

Keywords: pancreatic neuroendocrine tumour, immunotherapy, pembrolizumab, tumour mutational burden, TMB,

#4409 The value of NETest 2.0 in stratifying patients with suspected NEN for formal diagnostic evaluation – Real-world data

Introduction: An unmet need in NEN diagnosis is better risk stratification for individuals with suspected disease (based on symptoms or imaging), enabling efficient identification of those needing further evaluation and tissue diagnosis, thus speeding the process and reducing costs. NETest 2.0, a biomarker based on a 51-gene mRNA panel, was developed for diagnosing neuroendocrine neoplasia (NEN).

Conference:

Presenting Author: Chirindel A

Authors: Chirindel A, Wild D, Voegeli M, de Dosso S, Siebenhüner A,

Keywords: NETest, tumour biomarker, at-risk population, NEN,

#4219 MAPK and mTOR pathway activation is associated with chemotherapy resistance and a poor prognosis in G3 advanced NENs

Introduction: Neuroendocrine neoplasms (NENs) comprise a broad spectrum of disease ranging from slowly progressive to highly aggressive carcinomas.

Conference:

Presenting Author: Catoya J

Authors: Catoya J, Anton-Pascual B, Farinea G, Modrego A, La Salvia A,

Keywords: NEN, mTOR/MAPK pathway, molecular profiling, platinum-based,

#4105 Long-term outcomes for medically managed carcinoid heart disease patients: A retrospective, longitudinal survey

Introduction: Carcinoid Heart Disease (CHD) is a component of carcinoid syndrome. Patients with mild to moderate CHD and no indication for surgical intervention receive medical management (MMCHD).

Conference:

Presenting Author:

Authors: Fisher J, Montague K, Adigun R, Hayes A, Furtado-O'Mahony L,

Keywords: carcinoid syndrome, carcinoid heart disease, survival, medical management,

#4011 Differences in the microRNA expression of G1 and G2 pancreatic neuroendocrine tumors

Introduction: Targeted testing of microRNAs implicated in the biology of pancreatic neuroendocrine tumors (PNET) was performed via RT-QPCR to uncover differentially expressed microRNAs that could be used as diagnostic markers characteristic for tumor grade.

Conference:

Presenting Author:

Authors: Nyirő G, Szeredás B, Vékony B, Borka K, Zalatnai A,

Keywords: miRNA expression, PNET G1 and G2, RT-QPCR, hsa-miR-130b-3p, hsa-miR-194-5p, hsa-miR-96-5p, hsa-miR-106b, FFPE tissue,